How The Rhythm Pharmaceuticals (RYTM) Story Is Evolving After EMANATE And Imcivree Developments [Yahoo! Finance]
Rhythm Pharmaceuticals, Inc. (RYTM)
Last rhythm pharmaceuticals, inc. earnings: 3/8 08:12 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.rhythmtx.com
Company Research
Source: Yahoo! Finance
Rhythm Pharmaceuticals now carries a Fair Value price target of $137.27, a modest shift from $135.53 that reflects updated assumptions in the latest analyst models. This adjustment sits against a mixed backdrop of Street commentary, with the EMANATE readout prompting both upward and downward target revisions as analysts balance Imcivree's commercial path with the potential of next generation MC4R agonists. The following sections explain how to interpret these cross currents and outline what to watch as the Rhythm story continues to evolve. Analyst Price Targets don't always capture the full story. Head over to our Company Report to find new ways to value Rhythm Pharmaceuticals. What Wall Street Has Been Saying ?? Bullish Takeaways Several firms, including BofA, Citi, Wells Fargo, Guggenheim, and Citizens, lifted price targets earlier in 2026 after Rhythm shared Q4 Imcivree revenue details, TRANSCEND data in hypothalamic obesity, and progress toward potential label expansion.
Show less
Read more
Impact Snapshot
Event Time:
RYTM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RYTM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RYTM alerts
High impacting Rhythm Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
RYTM
News
- Rhythm Pharmaceuticals Announces Changes to Board of Directors [Yahoo! Finance]Yahoo! Finance
- Rhythm Pharmaceuticals Announces Changes to Board of DirectorsGlobeNewswire
- Is This Weight Loss Drug Stock a Buy After a New Approval? [Yahoo! Finance]Yahoo! Finance
- Rhythm Pharmaceuticals Receives Positive CHMP Opinion for IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity due to Hypothalamic Injury or Impairment [Yahoo! Finance]Yahoo! Finance
- Rhythm Pharmaceuticals Receives Positive CHMP Opinion for IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity due to Hypothalamic Injury or ImpairmentGlobeNewswire
RYTM
Earnings
- 2/26/26 - Beat
RYTM
Sec Filings
- 4/3/26 - Form 4
- 4/3/26 - Form 3
- 4/3/26 - Form 4
- RYTM's page on the SEC website